TN2011000316A1 - Derives de sulfonamides - Google Patents
Derives de sulfonamidesInfo
- Publication number
- TN2011000316A1 TN2011000316A1 TN2011000316A TN2011000316A TN2011000316A1 TN 2011000316 A1 TN2011000316 A1 TN 2011000316A1 TN 2011000316 A TN2011000316 A TN 2011000316A TN 2011000316 A TN2011000316 A TN 2011000316A TN 2011000316 A1 TN2011000316 A1 TN 2011000316A1
- Authority
- TN
- Tunisia
- Prior art keywords
- sulfonamide derivatives
- compounds
- preparation
- solvates
- pain
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/48—Nitrogen atoms not forming part of a nitro radical
- C07D263/50—Benzene-sulfonamido oxazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
- C07D275/02—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings
- C07D275/03—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/08—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D277/12—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/18—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/08—1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6536—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and sulfur atoms with or without oxygen atoms, as the only ring hetero atoms
- C07F9/6539—Five-membered rings
Abstract
La présente invention concerne des composés de formule (I) et leurs sels, leurs produits de solvatation ou leurs formes tautomères pharmaceutiquement acceptables, des procédés pour la préparation de, les intermédiaires utilisés dans la préparation de, et des compositions contenant ces composés , en particulier pour le traitement de la douleur
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14392009P | 2009-01-12 | 2009-01-12 | |
US24572609P | 2009-09-25 | 2009-09-25 | |
US25876009P | 2009-11-06 | 2009-11-06 | |
PCT/IB2010/050033 WO2010079443A1 (fr) | 2009-01-12 | 2010-01-06 | Dérivés sulfonamides |
Publications (1)
Publication Number | Publication Date |
---|---|
TN2011000316A1 true TN2011000316A1 (fr) | 2012-12-17 |
Family
ID=41818828
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TN2011000316A TN2011000316A1 (fr) | 2009-01-12 | 2011-06-21 | Derives de sulfonamides |
Country Status (42)
Families Citing this family (112)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR071363A1 (es) * | 2008-04-08 | 2010-06-16 | Gruenenthal Gmbh | Derivados de sulfonamida sustituida y su empleo en medicamentos para el tratamiento de enfermedades mediadas por receptores b1r. |
DK2385938T3 (en) * | 2009-01-12 | 2015-04-27 | Pfizer Ltd | Sulfonamidderivater |
DE102009058280A1 (de) * | 2009-12-14 | 2011-06-16 | Merck Patent Gmbh | Thiazolderivate |
CA2789606A1 (fr) | 2010-02-25 | 2011-09-01 | Pfizer Limited | Analogues peptidiques en tant qu'agonistes des recepteurs opioides |
ES2526675T3 (es) | 2010-07-09 | 2015-01-14 | Pfizer Limited | N-sulfonilbenzamidas como inhibidores de los canales de sodio dependientes de voltaje |
JP5830534B2 (ja) * | 2010-07-09 | 2015-12-09 | ファイザー・リミテッドPfizer Limited | 化合物 |
US9145407B2 (en) | 2010-07-09 | 2015-09-29 | Pfizer Limited | Sulfonamide compounds |
EP2593431B1 (fr) | 2010-07-12 | 2014-11-19 | Pfizer Limited | N-sulfonylbenzamides comme inhibiteurs des canaux sodiques voltage-dépendant |
JP2013536165A (ja) | 2010-07-12 | 2013-09-19 | ファイザー・リミテッド | 痛みの処置のためのnav1.7阻害薬としてのスルホンアミド誘導体 |
CA2804716A1 (fr) | 2010-07-12 | 2012-01-19 | Pfizer Limited | Composes chimiques |
ES2526541T3 (es) | 2010-07-12 | 2015-01-13 | Pfizer Limited | N-sulfonilbenzamidas como inhibidores de canales de sodio dependientes de voltaje |
CA2801032A1 (fr) | 2010-07-12 | 2012-01-19 | Pfizer Limited | Derives de n-sulfonylbenzamide utiles comme inhibiteurs du canal sodique voltage-dependant |
CA2811479A1 (fr) * | 2010-09-17 | 2012-03-22 | Purdue Pharma L.P. | Composes de pyridine et ses utilisations |
KR20140009311A (ko) | 2011-01-18 | 2014-01-22 | 암젠 인크 | Nav1.7 넉아웃 마우스 및 이의 용도 |
WO2012120398A1 (fr) | 2011-03-04 | 2012-09-13 | Pfizer Limited | Dérivés de carboxamide substitués par aryle en tant que modulateurs de trpm8 |
MX2013011612A (es) | 2011-04-05 | 2013-10-17 | Pfizer Ltd | Derivados de pirrolo[2,3-d]pirimidina como inhibidores de quinasa relacionados con tropomiosina. |
UY34171A (es) * | 2011-07-01 | 2013-01-31 | Gilead Sciences Inc | Compuestos heterocíclicos fusionados como moduladores del canal iónico |
ES2564366T3 (es) | 2011-07-13 | 2016-03-22 | Pfizer Limited | Análogos de encefalina |
MX364378B (es) | 2011-08-30 | 2019-01-21 | Chdi Foundation Inc | Inhibidores de la quinurenina-3-monooxigenasa, sus composiciones farmaceuticas y metodos para uso. |
JP5363636B2 (ja) * | 2011-10-21 | 2013-12-11 | ファイザー・リミテッド | 新規な塩および医学的使用 |
IN2014CN02959A (fr) | 2011-10-28 | 2015-07-03 | Merck Sharp & Dohme | |
JP6014155B2 (ja) * | 2011-10-31 | 2016-10-25 | ゼノン・ファーマシューティカルズ・インコーポレイテッドXenon Pharmaceuticals Inc. | ビアリールエーテルスルホンアミドおよび治療剤としてのそれらの使用 |
KR20140091022A (ko) * | 2011-10-31 | 2014-07-18 | 제논 파마슈티칼스 인크. | 벤젠술폰아미드 화합물 및 치료제로서의 그의 용도 |
WO2013086229A1 (fr) | 2011-12-07 | 2013-06-13 | Amgen Inc. | Inhibiteurs aryle et hétéroaryle bicycliques des canaux calciques |
WO2013093688A1 (fr) | 2011-12-19 | 2013-06-27 | Pfizer Limited | Dérivés sulfonamides et leur utilisation en tant qu'inhibiteurs de vgsc |
US20150291514A1 (en) * | 2012-01-04 | 2015-10-15 | Pfizer Limted | N-Aminosulfonyl Benzamides |
US8889741B2 (en) | 2012-02-09 | 2014-11-18 | Daiichi Sankyo Company, Limited | Cycloalkane derivatives |
WO2013161928A1 (fr) * | 2012-04-26 | 2013-10-31 | 塩野義製薬株式会社 | Dérivé oxazolotriazole et composition médicamenteuse contenant celui-ci |
WO2013161929A1 (fr) * | 2012-04-26 | 2013-10-31 | 塩野義製薬株式会社 | Dérivé de pyridinyl-morpholinone et composition médicamenteuse contenant celui-ci |
MX2014014234A (es) | 2012-05-22 | 2015-05-07 | Genentech Inc | Benzamidas n-sustituidas y su uso en el tratamiento del dolor. |
BR112014031068A2 (pt) | 2012-06-12 | 2017-06-27 | Abbvie Inc | derivados piridinona e piridazinona |
CA2878478A1 (fr) | 2012-07-06 | 2014-01-09 | Genentech, Inc. | Benzamides n-substitues et leurs procedes d'utilisation |
JP2015531393A (ja) | 2012-10-04 | 2015-11-02 | ファイザー・リミテッドPfizer Limited | トロポミオシン関連キナーゼ阻害剤 |
JP2015531395A (ja) | 2012-10-04 | 2015-11-02 | ファイザー・リミテッドPfizer Limited | ピロロ[3,2−c]ピリジントロポミオシン関連キナーゼ阻害剤 |
EP2903989A1 (fr) | 2012-10-04 | 2015-08-12 | Pfizer Limited | Inhibiteurs de kinase associée à la tropomyosine pyrrolo[2,3-d]pyrimidine |
ES2828503T3 (es) * | 2012-10-15 | 2021-05-26 | Dae Woong Pharma | Bloqueadores de los canales de sodio, método de preparación de los mismos y uso de los mismos |
CN104869992A (zh) | 2012-10-26 | 2015-08-26 | 默沙东公司 | 具有电压门控性钠通道选择性活性的n-取代的吲唑磺酰胺化合物 |
JO3225B1 (ar) * | 2012-11-27 | 2018-03-08 | Lilly Co Eli | 6-((s)-1-{1-[5-(2-هيدروكسي-إيثوكسي)-بيريدين-2-يل]-1h-بيرازول-3-يل}إيثيل)-3h-1 ، 3-بنزو ثيازول-2- أون باعتباره مضاد مستقبل ampa يعتمد على tarp- جاما 8 |
UA112028C2 (uk) | 2012-12-14 | 2016-07-11 | Пфайзер Лімітед | Похідні імідазопіридазину як модулятори гамка-рецептора |
WO2014153037A1 (fr) | 2013-03-14 | 2014-09-25 | Genentech, Inc. | Triazolopyridines substituées et leurs procédés d'utilisation |
CN105073114B (zh) | 2013-03-14 | 2017-07-28 | 第一三共株式会社 | 用于呼吸疾病的药物 |
CN105073728A (zh) | 2013-03-15 | 2015-11-18 | 全球血液疗法股份有限公司 | 化合物及其用于调节血红蛋白的用途 |
RU2015143834A (ru) | 2013-03-15 | 2017-04-24 | Дженентек, Инк. | Замещенные бензоксазолы и способы их применения |
JP6449845B2 (ja) * | 2013-03-15 | 2019-01-09 | クロモセル コーポレイション | 疼痛の処置のためのナトリウムチャネルモジュレーター |
EP2792360A1 (fr) | 2013-04-18 | 2014-10-22 | IP Gesellschaft für Management mbH | (1aR,12bS)-8-cyclohexyl-11-fluoro-N-((1-methylcyclopropyl)sulfonyl)-1a-((3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl)carbonyl)-1,1a,2,2b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide pour utilisation dans le traitement de HCV |
TW201512171A (zh) | 2013-04-19 | 2015-04-01 | Pfizer Ltd | 化學化合物 |
TW201443025A (zh) | 2013-04-19 | 2014-11-16 | Pfizer Ltd | 化學化合物 |
MD20150122A2 (ro) | 2013-06-27 | 2016-05-31 | Pfizer Inc. | Compuşi heteroaromatici şi utilizarea lor ca liganzi ai dopaminei D1 |
HRP20201701T8 (hr) * | 2013-09-09 | 2022-01-07 | Peloton Therapeutics, Inc. | Aril eteri i njihove uporabe |
AU2014318979B2 (en) * | 2013-09-10 | 2019-03-28 | Chromocell Corporation | Sodium channel modulators for the treatment of pain and diabetes |
EA201992707A1 (ru) | 2013-11-18 | 2020-06-30 | Глобал Блад Терапьютикс, Инк. | Соединения и их применения для модуляции гемоглобина |
EP3074377B1 (fr) | 2013-11-27 | 2018-10-17 | Genentech, Inc. | Benzamides substitués et leurs méthodes d'utilisation |
WO2015092610A1 (fr) | 2013-12-20 | 2015-06-25 | Pfizer Limited | Inhibiteurs de kinase apparentés à la n-acylpipéridine éther tropomyosine |
EP3131891A1 (fr) | 2014-04-15 | 2017-02-22 | Pfizer Inc. | Inhibiteurs de kinases apparentées à la tropomyosine contenant à la fois un 1h-pyrazole et un fragment pyrimidine |
EP3140298A1 (fr) | 2014-05-07 | 2017-03-15 | Pfizer Inc. | Inhibiteurs de kinases apparentées à la tropomyosine |
JP2017516803A (ja) | 2014-05-30 | 2017-06-22 | ファイザー・インク | ナトリウムチャネル阻害剤として有用なベンゼンスルホンアミド |
ES2664810T3 (es) | 2014-06-12 | 2018-04-23 | Pfizer Limited | Derivados de imidazopiridazina como moduladores de la actividad del receptor GABAA |
CN106715418A (zh) | 2014-07-07 | 2017-05-24 | 基因泰克公司 | 治疗化合物及其使用方法 |
WO2016009296A1 (fr) | 2014-07-16 | 2016-01-21 | Pfizer Inc. | Inhibiteurs de kinase liés à la n-acylpipéridine éther tropomyosine |
WO2016009303A1 (fr) | 2014-07-17 | 2016-01-21 | Pfizer Inc. | Associations de produits pharmaceutiques comprenant de la gabapentine ou de la prégabaline avec des inhibiteurs de nav1.7 |
MX2017000779A (es) | 2014-07-17 | 2017-07-27 | Chdi Foundation Inc | Metodos y composiciones para el tratamiento de trastornos relacionados con el vih. |
WO2016020784A1 (fr) | 2014-08-05 | 2016-02-11 | Pfizer Inc. | Inhibiteurs de kinases apparentées à la n-acylpyrrolidine éther tropomyosine |
WO2016034971A1 (fr) | 2014-09-04 | 2016-03-10 | Pfizer Limited | Dérivés sulfonamides utilisés en tant qu'inhibiteurs d'urat1 |
WO2016040315A1 (fr) * | 2014-09-09 | 2016-03-17 | Chromocell Corporation | Inhibiteurs sélectifs de nav1.7 pour le traitement du diabète |
WO2016067143A1 (fr) | 2014-10-28 | 2016-05-06 | Pfizer Inc. | Composés n- (2-alkylèneimino-3-phénylpropyl)acétamide et leur utilisation contre la douleur et le prurit par inhibition des canaux trpa1 |
KR102412146B1 (ko) | 2015-02-11 | 2022-06-22 | 주식회사 아이엔테라퓨틱스 | 소디움 채널 차단제 |
US10807948B2 (en) | 2015-03-11 | 2020-10-20 | Peloton Therapeutics, Inc. | Aromatic compounds and uses thereof |
EP3268362B1 (fr) | 2015-03-11 | 2021-10-20 | Peloton Therapeutics, Inc. | Pyridines substituées et leurs utilisations |
WO2016145032A1 (fr) | 2015-03-11 | 2016-09-15 | Peloton Therapeutics, Inc. | Compositions utilisées pour traiter l'hypertension artérielle pulmonaire |
US10512626B2 (en) | 2015-03-11 | 2019-12-24 | Peloton Therapeautics, Inc. | Compositions for use in treating glioblastoma |
US10335388B2 (en) | 2015-04-17 | 2019-07-02 | Peloton Therapeutics, Inc. | Combination therapy of a HIF-2-alpha inhibitor and an immunotherapeutic agent and uses thereof |
MX2017014715A (es) | 2015-05-22 | 2018-03-16 | Genentech Inc | Benzamidas sustituidas y metodos para utilizarlas. |
EP3865472A1 (fr) * | 2015-06-16 | 2021-08-18 | ATXA Therapeutics Limited | Antagonistes du récepteur de thromboxane |
JP2018526371A (ja) | 2015-08-27 | 2018-09-13 | ジェネンテック, インコーポレイテッド | 治療化合物及びその使用方法 |
CA2999769A1 (fr) | 2015-09-28 | 2017-04-06 | Genentech, Inc. | Composes therapeutiques et leurs procedes d'utilisation |
US10316026B2 (en) | 2015-11-06 | 2019-06-11 | Daiichi Sankyo Company, Limited | Method for removing dimethoxybenzyl group |
EP3375782B1 (fr) | 2015-11-13 | 2020-07-29 | Daewoong Pharmaceutical Co., Ltd. | Bloqueur des canaux sodiques |
MA43304A (fr) | 2015-11-25 | 2018-10-03 | Genentech Inc | Benzamides substitués utiles en tant que bloqueurs de canaux sodiques |
WO2017100593A1 (fr) | 2015-12-09 | 2017-06-15 | Luc Therapeutics | Modulateurs de récepteurs nmda de type thiénopyrimidinone et utilisations associées |
LT3386591T (lt) | 2015-12-09 | 2020-10-12 | Cadent Therapeutics, Inc. | Heteroaromatiniai nmda receptoriaus moduliatoriai ir jų panaudojimas |
US10538523B2 (en) | 2015-12-10 | 2020-01-21 | Pfizer Limited | 4-(biphen-3-yl)-1H-pyrazolo[3,4-c]pyridazine derivatives of formula (I) as GABA receptor modulators for use in the treatment of epilepsy and pain |
CA3008614A1 (fr) * | 2015-12-18 | 2017-06-22 | Merck Sharp & Dohme Corp. | Composes d'arylsulfonamide a liaisons diamino-alkylamino ayant une activite selective vis-a-vis des canaux sodiques voltage-dependants |
KR20180095598A (ko) | 2015-12-18 | 2018-08-27 | 머크 샤프 앤드 돔 코포레이션 | 전압-게이팅 나트륨 채널에서 선택적 활성을 갖는 히드록시알킬아민- 및 히드록시시클로알킬아민-치환된 디아민-아릴술폰아미드 화합물 |
WO2017153952A1 (fr) * | 2016-03-10 | 2017-09-14 | Glaxosmithkline Intellectual Property Development Limited | Dérivés de 5-sulfamoyl-2-hydroxybenzamide |
WO2017165204A1 (fr) | 2016-03-22 | 2017-09-28 | Merck Sharp & Dohme Corp. | Composés de n1-phénylpropane-1,2-diamine ayant une activité sélective dans des canaux sodiques sensibles à la tension |
CN106397426A (zh) * | 2016-03-29 | 2017-02-15 | 广东环境保护工程职业学院 | 一种1,3,4-噻二唑类化合物及其制备方法 |
CN106397425A (zh) * | 2016-03-29 | 2017-02-15 | 广东环境保护工程职业学院 | 一种1,3,4-噻二唑类化合物及其制备方法 |
EP3854782A1 (fr) | 2016-03-30 | 2021-07-28 | Genentech, Inc. | Benzamides substitués et leurs procédés d'utilisation |
US10246453B2 (en) | 2016-05-20 | 2019-04-02 | Xenon Pharmaceuticals Inc. | Benzenesulfonamide compounds and their use as therapeutic agents |
WO2017202376A1 (fr) * | 2016-05-26 | 2017-11-30 | 南京明德新药研发股份有限公司 | Dérivé de sulfamide |
SG11201903348UA (en) * | 2016-10-17 | 2019-05-30 | Genentech Inc | Therapeutic compounds and methods of use thereof |
CA3042004A1 (fr) * | 2016-12-09 | 2018-06-14 | Xenon Pharmaceuticals Inc. | Composes de benzenesulfonamide et leur utilisation en tant qu'agents therapeutiques |
CA3047403A1 (fr) | 2016-12-22 | 2018-06-28 | Cadent Therapeutics, Inc. | Modulateurs des recepteurs nmda et utilisations de ceux-ci |
WO2018172616A1 (fr) * | 2017-03-23 | 2018-09-27 | Orion Corporation | Procédé de préparation d'un inhibiteur de kinase à structure sulfonamide |
WO2018175707A1 (fr) | 2017-03-24 | 2018-09-27 | Genentech, Inc. | Dérivés de 4-pipéridine-n-(pyrimidin-4-yl) chromane-7-sulfonamide en tant qu'inhibiteurs de canaux sodiques |
JP2020532507A (ja) * | 2017-08-31 | 2020-11-12 | ラクオリア創薬株式会社 | Ttx−s遮断薬としてのビアリールオキシ誘導体 |
US11028075B2 (en) | 2018-02-26 | 2021-06-08 | Genentech, Inc. | Therapeutic compounds and methods of use thereof |
US10947251B2 (en) | 2018-03-30 | 2021-03-16 | Genentech, Inc. | Therapeutic compounds and methods of use thereof |
WO2019200369A1 (fr) * | 2018-04-13 | 2019-10-17 | Chromocell Corporation | Composés et méthodes d'utilisation de composés pour la prévention ou le traitement de lésions des nerfs périphériques |
TW202003490A (zh) * | 2018-05-22 | 2020-01-16 | 瑞士商赫孚孟拉羅股份公司 | 治療性化合物及其使用方法 |
CN112262142B (zh) | 2018-06-13 | 2023-11-14 | 泽农医药公司 | 苯磺酰胺化合物及其作为治疗剂的用途 |
GB201810092D0 (en) * | 2018-06-20 | 2018-08-08 | Ctxt Pty Ltd | Compounds |
HUE062566T2 (hu) | 2018-08-03 | 2023-11-28 | Novartis Ag | Heteroaromás NMDA receptor modulátorok és alkalmazásaik |
CA3104913A1 (fr) | 2018-08-31 | 2020-03-05 | Xenon Pharmaceuticals Inc. | Composes de sulfonamide substitues par heteroaryle et leur utilisation en tant qu'inhibiteurs de canaux sodiques |
AU2019331005B2 (en) | 2018-08-31 | 2024-03-28 | Xenon Pharmaceuticals Inc. | Heteroaryl-substituted sulfonamide compounds and their use as therapeutic agents |
EP3891157A4 (fr) | 2018-12-05 | 2022-08-31 | Merck Sharp & Dohme Corp. | Composés d'aryle sulfonamide substitués par 4-amino ou 4-alcoxy ayant une activité sélective dans des canaux sodiques sensibles à la tension |
CN111285825B (zh) * | 2018-12-10 | 2023-02-17 | 中国科学院上海药物研究所 | 一类苯磺酰胺取代的衍生物,其制法及其用途 |
CN112759559B (zh) * | 2019-11-06 | 2022-08-12 | 成都康弘药业集团股份有限公司 | 作为钠通道阻滞剂的磺酰胺类化合物及其用途 |
WO2021247634A1 (fr) * | 2020-06-03 | 2021-12-09 | Dana-Farber Cancer Institute, Inc. | Inhibiteurs du domaine associé d'activation transcriptionnel (tead) et utilisations |
CN114073698B (zh) * | 2020-08-20 | 2023-03-31 | 山西泰睿鑫科技有限公司 | 一种止痛止痒药物组合物及其应用方法 |
CN112625030A (zh) * | 2020-12-25 | 2021-04-09 | 杭州澳赛诺生物科技有限公司 | 一种一锅法合成n-保护3-溴代吡唑的合成方法 |
US11918572B2 (en) * | 2022-01-28 | 2024-03-05 | Rebel Medicine Inc | Pharmaceutical compositions for treating pain |
Family Cites Families (83)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3905971A (en) | 1971-03-29 | 1975-09-16 | Pfizer | 2-Phenyl-as-triazine-3,5(2H,4H)diones |
DE3531919A1 (de) | 1985-09-07 | 1987-03-19 | Hoechst Ag | Substituierte 2-phenyl-hexahydro-1,2,4-triazin-3,5-dione, verfahren zu ihrer herstellung, sie enthaltende mittel und ihre verwendung |
DE3540654A1 (de) * | 1985-11-13 | 1987-05-14 | Schering Ag | Phenoxy-substituierte ss-carbolinderivate, ihre herstellung und ihre verwendung als arzneimittel |
US5591761A (en) | 1993-05-20 | 1997-01-07 | Texas Biotechnology Corporation | Thiophenyl-, furyl-and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin |
JPH0264538A (ja) | 1988-08-31 | 1990-03-05 | Fuji Photo Film Co Ltd | ハロゲン化銀カラー写真感光材料 |
US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
EP0532239B1 (fr) | 1991-09-10 | 1995-12-13 | Zeneca Limited | Dérivés de benzenesulfonamide comme inhibiteurs de 5-lipoxygenase |
GB2263635A (en) | 1992-01-28 | 1993-08-04 | Merck & Co Inc | Substitiuted triazoles as neurotensin antagonists |
US5219856A (en) * | 1992-04-06 | 1993-06-15 | E. I. Du Pont De Nemours And Company | Angiotensin-II receptor blocking, heterocycle substituted imidazoles |
NZ247440A (en) | 1992-05-06 | 1995-04-27 | Squibb & Sons Inc | Phenyl sulphonamide derivatives, preparation and pharmaceutical compositions thereof |
GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
AU712057B2 (en) | 1996-06-07 | 1999-10-28 | Merck & Co., Inc. | Oxadiazole benzenesulfonamides as selective beta3 agonists for the treatment of diabetes and obesity |
US6548524B2 (en) | 1996-10-16 | 2003-04-15 | American Cyanamid Company | Preparation and use of ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloproteinase and TACE inhibitors |
WO2000035298A1 (fr) | 1996-11-27 | 2000-06-22 | Wm. Wrigley Jr. Company | Chewing-gum contenant des agents medicamenteux actifs |
GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
EP0937723A1 (fr) | 1998-02-18 | 1999-08-25 | Roche Diagnostics GmbH | Nouveaux sulfonamides, procédé pour leur préparation et médicaments les contenant |
PA8469501A1 (es) * | 1998-04-10 | 2000-09-29 | Pfizer Prod Inc | Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico |
PA8469401A1 (es) * | 1998-04-10 | 2000-05-24 | Pfizer Prod Inc | Derivados biciclicos del acido hidroxamico |
DE60003863T2 (de) * | 1999-03-31 | 2004-04-22 | Pfizer Products Inc., Groton | Dioxocyclopentylhydroxamsäure |
MXPA01012265A (es) * | 1999-05-28 | 2002-07-30 | Pfizer Prod Inc | Hidroxiamidas de acidos 3-(arilsulfonilamino)-tetrahidropiran-3-carboxilicos. |
HN2000000052A (es) * | 1999-05-28 | 2001-02-02 | Pfizer Prod Inc | Hidroxiamidas de acidos 3- (arilsulfonilamino)- tetrahidrofuran-3-carboxilicos. |
AU6180600A (en) | 1999-07-29 | 2001-02-19 | Ono Pharmaceutical Co. Ltd. | Sulfonamide derivatives and remedies for allodynia |
EP1088819B1 (fr) | 1999-09-30 | 2005-06-15 | Pfizer Products Inc. | Dérivés de 6-azauracil utiles en tant que ligands du récepteur thyroide |
WO2001056989A2 (fr) | 2000-02-01 | 2001-08-09 | Cor Therapeutics, Inc. | INHIBITEURS DU FACTEUR Xa CONTENANT DU PHENYLENE BIVALENT |
WO2001087293A1 (fr) | 2000-05-19 | 2001-11-22 | Takeda Chemical Industries, Ltd. | Inhibiteurs de la ?-secretase |
EP1217000A1 (fr) | 2000-12-23 | 2002-06-26 | Aventis Pharma Deutschland GmbH | Inhibiteurs du factor Xa et factor VIIa |
JP2003081937A (ja) * | 2001-09-07 | 2003-03-19 | Bayer Ag | ベンゼンスルホンアミド誘導体 |
AU2002347336A1 (en) | 2001-12-05 | 2003-06-17 | Astrazeneca Ab | Quinoline derivatives |
US20030158186A1 (en) | 2001-12-21 | 2003-08-21 | Fady Malik | Compositions and methods for treating heart failure |
JP4881559B2 (ja) | 2002-06-27 | 2012-02-22 | ノボ・ノルデイスク・エー/エス | 治療薬としてのアリールカルボニル誘導体 |
KR20050039846A (ko) | 2002-08-09 | 2005-04-29 | 아스트라제네카 에이비이 | 메타보트로픽 글루타메이트 수용체-5의 조절제로서의옥사디아졸 |
US7169797B2 (en) | 2003-02-14 | 2007-01-30 | Abbott Laboratories | Protein-tyrosine phosphatase inhibitors and uses thereof |
WO2004084898A1 (fr) * | 2003-03-24 | 2004-10-07 | Actimis Pharmaceuticals, Inc. | Derives de 2-phenoxy- et 2-phenylsulfonamide a activite antagoniste de ccr3 pour le traitement de l'asthme et d'autres troubles inflammatoires ou immunologiques |
EP1631558A1 (fr) | 2003-05-21 | 2006-03-08 | Biovitrum Ab | Inhibiteurs de 11-beta-hydroxy steroide deshydrogenase de type i |
US7915293B2 (en) | 2003-05-30 | 2011-03-29 | Rigel Pharmaceuticals, Inc. | Ubiquitin ligase inhibitors |
WO2005000309A2 (fr) | 2003-06-27 | 2005-01-06 | Ionix Pharmaceuticals Limited | Composes chimiques |
WO2005016267A2 (fr) | 2003-08-06 | 2005-02-24 | Pfizer Products Inc. | Composes d'oxazole destines au traitement de troubles neurodegenerescents |
WO2005013914A2 (fr) * | 2003-08-08 | 2005-02-17 | Vertex Pharmaceuticals Incorporated | Compositions utilisees comme inhibiteurs de canaux sodium voltage dependants |
US7378414B2 (en) | 2003-08-25 | 2008-05-27 | Abbott Laboratories | Anti-infective agents |
WO2005054176A1 (fr) | 2003-11-25 | 2005-06-16 | Eli Lilly And Company | Modulateurs des recepteurs actives par les proliferateurs de peroxysomes |
CA2549598A1 (fr) * | 2003-12-15 | 2005-06-30 | Japan Tobacco Inc. | Composes de n-sulfonylaminocyclopropane n-substitue et leur utilisation pharmaceutique |
EP1745029A1 (fr) | 2004-04-30 | 2007-01-24 | Warner-Lambert Company LLC | Composes de morpholine substitues permettant de traiter des troubles du systeme nerveux central |
EA011279B1 (ru) | 2004-05-24 | 2009-02-27 | Ф. Хоффманн-Ля Рош Аг | (4-метокси-7-морфолин-4-илбензотиазол-2-ил)-амид 4-гидрокси-4-метилпиперидин-1-карбоновой кислоты |
US20050282818A1 (en) | 2004-06-22 | 2005-12-22 | Rigel Pharmaceuticals, Inc. | Ubiquitin ligase inhibitors |
MX2007001215A (es) | 2004-08-06 | 2007-04-17 | Otsuka Pharma Co Ltd | Compuestos aromaticos. |
PE20060598A1 (es) | 2004-09-13 | 2006-08-21 | Ono Pharmaceutical Co | Derivado heterociclo conteniendo nitrogeno como antagonista de quimiocina ccr5 |
SE0402735D0 (sv) | 2004-11-09 | 2004-11-09 | Astrazeneca Ab | Novel compounds |
WO2006060762A2 (fr) | 2004-12-03 | 2006-06-08 | Arena Pharmaceuticals, Inc. | Derives de pyrazole en tant que modulateurs du recepteur de serotinine 5-ht2a utiles dans le traitement de troubles associes a ce recepteur |
EP2354126B1 (fr) | 2005-01-14 | 2013-09-25 | ChemoCentryx, Inc. | Sulfonamides d'hétéroarylamide et CCR2 |
WO2006089311A1 (fr) | 2005-02-15 | 2006-08-24 | Amgen Inc. | Ligands des recepteurs vanilloides et leurs utilisations therapeutiques |
US7816382B2 (en) | 2005-06-27 | 2010-10-19 | Bristol-Myers Squibb Company | Linear urea mimics antagonists of P2Y1 receptor useful in the treatment of thrombotic condition |
EP1899299B1 (fr) | 2005-06-27 | 2010-10-20 | Bristol-Myers Squibb Company | Antagonistes cycliques a liaison c du recepteur p2y1, utiles pour traiter des etats pathologiques thrombotiques |
WO2007034312A2 (fr) | 2005-09-23 | 2007-03-29 | Pfizer Products Inc. | Composes therapeutiques |
JP2009510144A (ja) | 2005-10-06 | 2009-03-12 | サノフィ−アベンティス | 4−オキシ−n−[1,3,4]−チアジアゾール−2−イル−ベンゼンスルホンアミド類、それらの製造方法及びそれらの医薬品としての使用 |
CA2626190A1 (fr) * | 2005-10-21 | 2007-05-03 | Vertex Pharmaceuticals Incorporated | Derives modulant des canaux ioniques |
AR058296A1 (es) | 2005-12-09 | 2008-01-30 | Kalypsys Inc | Inhibidores de histona desacetilasa y composicion farmaceutica |
WO2007076034A2 (fr) | 2005-12-21 | 2007-07-05 | Abbott Laboratories | Composes antiviraux |
JP5089185B2 (ja) | 2006-02-02 | 2012-12-05 | 大塚製薬株式会社 | コラーゲン産生抑制剤。 |
ES2452031T3 (es) | 2006-02-03 | 2014-03-31 | Eli Lilly & Company | Compuestos y procedimientos para modular receptores FX |
WO2007118859A1 (fr) | 2006-04-14 | 2007-10-25 | Abbott Gmbh & Co. Kg | Composés aryloxyéthylamine appropriés pour le traitement des troubles qui répondent a une modulation du récepteur d3 de la dopamine |
GB0608386D0 (en) | 2006-04-27 | 2006-06-07 | Senexis Ltd | Compounds |
ES2436028T3 (es) | 2006-06-23 | 2013-12-26 | Radius Health, Inc. | Tratamiento de síntomas vasomotores con moduladores selectivos de receptores de estrógeno |
MX2009003763A (es) | 2006-10-05 | 2009-04-22 | Janssen Pharmaceutica Nv | Inhibidores de metaloproteasa derivados de heterociclicos. |
US20080255155A1 (en) | 2006-10-18 | 2008-10-16 | Stephane Raeppel | Kinase inhibitors and uses thereof |
DK2076508T3 (da) | 2006-10-18 | 2011-02-21 | Pfizer Prod Inc | Biaryl-ether-urinstof-forbindelser |
WO2008050200A1 (fr) | 2006-10-24 | 2008-05-02 | Pfizer Products Inc. | Composés d'oxadiazole comme antagonistes des canaux calciques |
WO2008057280A1 (fr) | 2006-10-27 | 2008-05-15 | Amgen Inc. | Composés à cycles multiples et procédés d'utilisation |
CA2695613A1 (fr) * | 2006-12-19 | 2008-06-26 | Pharmos Corporation | Derives sulfonamides avec indications therapeutiques |
AU2007338792B2 (en) | 2006-12-20 | 2012-05-31 | Amgen Inc. | Substituted heterocycles and methods of use |
JP2008214222A (ja) | 2007-03-01 | 2008-09-18 | Tokyo Medical & Dental Univ | フェノール誘導体及びその医薬用途 |
WO2008118758A1 (fr) * | 2007-03-23 | 2008-10-02 | Icagen, Inc. | Inhibiteurs de canaux ioniques |
ES2323927B1 (es) | 2007-03-30 | 2010-05-14 | Laboratorios Salvat, S.A. | Metodo in vitro no invasivo para detectar carcinoma transicional de vejiga. |
US7960567B2 (en) | 2007-05-02 | 2011-06-14 | Amgen Inc. | Compounds and methods useful for treating asthma and allergic inflammation |
BRPI0810202A2 (pt) | 2007-05-03 | 2014-10-21 | Pfizer Ltd | Derivados de piridina |
PE20090288A1 (es) * | 2007-05-10 | 2009-04-03 | Smithkline Beecham Corp | Derivados de quinoxalina como inhibidores de la pi3 quinasa |
US8124610B2 (en) | 2007-07-13 | 2012-02-28 | Icagen Inc. | Sodium channel inhibitors |
US20090069288A1 (en) | 2007-07-16 | 2009-03-12 | Breinlinger Eric C | Novel therapeutic compounds |
WO2009017719A2 (fr) | 2007-07-30 | 2009-02-05 | Encysive Pharmaceuticals, Inc. | Modulateurs du récepteur ccr9 et leurs procédés d'utilisation |
CA2705947C (fr) | 2007-11-16 | 2016-08-09 | Rigel Pharmaceuticals, Inc. | Composes de carboxamide, de sulfonamide et d'amine pour des troubles metaboliques |
MX2010011258A (es) | 2008-04-14 | 2011-06-20 | Univ Texas | Inhibidores de molecula pequeña del dominio de homologia de pleckstrin y metodos para usar los mismos. |
JP2011520785A (ja) | 2008-04-16 | 2011-07-21 | バイオリポックス エービー | 薬剤としての使用のためのビスアリール化合物 |
DK2385938T3 (en) * | 2009-01-12 | 2015-04-27 | Pfizer Ltd | Sulfonamidderivater |
-
2010
- 2010-01-06 DK DK10702740T patent/DK2385938T3/en active
- 2010-01-06 KR KR1020117018770A patent/KR101345497B1/ko not_active IP Right Cessation
- 2010-01-06 GE GEAP201012293A patent/GEP20135992B/en unknown
- 2010-01-06 MX MX2011007424A patent/MX2011007424A/es active IP Right Grant
- 2010-01-06 RS RS20150244A patent/RS53941B1/en unknown
- 2010-01-06 ES ES10702740.1T patent/ES2536191T3/es active Active
- 2010-01-06 UA UAA201108581A patent/UA105911C2/uk unknown
- 2010-01-06 CU CU2011000145A patent/CU24099B1/es active IP Right Grant
- 2010-01-06 HU HUE10702740A patent/HUE025013T2/hu unknown
- 2010-01-06 PE PE2011001300A patent/PE20120008A1/es not_active Application Discontinuation
- 2010-01-06 CN CN201080011374.3A patent/CN102348697B/zh not_active Expired - Fee Related
- 2010-01-06 BR BRPI1006128A patent/BRPI1006128A2/pt not_active IP Right Cessation
- 2010-01-06 MA MA34014A patent/MA32965B1/fr unknown
- 2010-01-06 JP JP2011544954A patent/JP5053459B2/ja not_active Expired - Fee Related
- 2010-01-06 CA CA2747419A patent/CA2747419C/fr not_active Expired - Fee Related
- 2010-01-06 AU AU2010204118A patent/AU2010204118B2/en not_active Ceased
- 2010-01-06 WO PCT/IB2010/050033 patent/WO2010079443A1/fr active Application Filing
- 2010-01-06 PL PL10702740T patent/PL2385938T3/pl unknown
- 2010-01-06 EP EP10702740.1A patent/EP2385938B1/fr active Active
- 2010-01-06 EA EA201170922A patent/EA020460B1/ru not_active IP Right Cessation
- 2010-01-06 PT PT107027401T patent/PT2385938E/pt unknown
- 2010-01-06 PE PE2014001348A patent/PE20142099A1/es not_active Application Discontinuation
- 2010-01-06 AP AP2011005788A patent/AP2811A/xx active
- 2010-01-06 MY MYPI2011003158A patent/MY157017A/en unknown
- 2010-01-06 NZ NZ593473A patent/NZ593473A/xx not_active IP Right Cessation
- 2010-01-07 TW TW099100267A patent/TWI419897B/zh not_active IP Right Cessation
- 2010-01-07 TW TW102136757A patent/TWI494317B/zh not_active IP Right Cessation
- 2010-01-11 AR ARP100100053A patent/AR075005A1/es unknown
- 2010-01-11 UY UY0001032379A patent/UY32379A/es not_active Application Discontinuation
- 2010-01-12 HN HN2010000084A patent/HN2010000084A/es unknown
- 2010-01-12 US US12/685,913 patent/US8153814B2/en not_active Expired - Fee Related
-
2011
- 2011-06-13 IL IL213517A patent/IL213517A/en not_active IP Right Cessation
- 2011-06-21 TN TN2011000316A patent/TN2011000316A1/fr unknown
- 2011-06-28 CR CR20110370A patent/CR20110370A/es unknown
- 2011-07-06 CL CL2011001658A patent/CL2011001658A1/es unknown
- 2011-07-08 SV SV2011003970A patent/SV2011003970A/es unknown
- 2011-07-08 DO DO2011000218A patent/DOP2011000218A/es unknown
- 2011-07-11 GT GT201100195A patent/GT201100195A/es unknown
- 2011-07-11 NI NI201100137A patent/NI201100137A/es unknown
- 2011-07-12 EC EC2011011198A patent/ECSP11011198A/es unknown
- 2011-07-22 CO CO11092086A patent/CO6400220A2/es active IP Right Grant
- 2011-07-27 ZA ZA2011/05530A patent/ZA201105530B/en unknown
-
2012
- 2012-02-20 US US13/400,356 patent/US8541588B2/en not_active Expired - Fee Related
- 2012-02-28 HK HK12102006.4A patent/HK1161253A1/xx not_active IP Right Cessation
-
2013
- 2013-08-16 US US13/968,561 patent/US8907101B2/en not_active Expired - Fee Related
-
2015
- 2015-03-30 HR HRP20150355TT patent/HRP20150355T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TN2011000316A1 (fr) | Derives de sulfonamides | |
TN2009000450A1 (fr) | Derives de pyridine | |
TNSN07022A1 (fr) | Derives de pyridine | |
MA29926B1 (fr) | Derives de pyrazine | |
MA30405B1 (fr) | Derives de 4-benzylphtalazinone substitues en 2 en tant qu'antagonistes des histamines hl et h3 | |
MA29791B1 (fr) | Composes therapeutiques. | |
MA30911B1 (fr) | Nouveaux derives de sulfonamide en tant qu'antagonistes de bradykinine | |
MA38138A1 (fr) | Dérivés inédits de quinolone | |
TN2009000033A1 (fr) | Derives de pyrazole servant d'inhibiteurs du cytochrome p450 | |
MA33450B1 (fr) | Dérivés d'oxazine et leur utilisation en tant qu'inhibiteurs de bace pour le traitement de troubles neurologiques | |
MA32466B1 (fr) | Derives de triazole utiles pour le traitement de maladies | |
MA30912B1 (fr) | Nouveaux derives de phenylsulfamoyl-benzamide en tant qu'antagonistes de la bradykinine | |
MA27560A1 (fr) | Nouveaux derives de fluorglycoside heterocycliques, produits pharmaceutiques contenant ces composes et leur utilisation | |
MA27801A1 (fr) | Nouveaux composes heterocycliques pour le traitement des affections inflammatoires et allergiques, leur procede de preparation et compositions pharmaceutiques les contenant | |
MA37142A2 (fr) | Dérivés de dihydro-benzo-oxazine et de dihydro-pyrido-oxazine | |
MA32135B1 (fr) | Inhibiteurs de pim kinase et leurs procedes d'utilisation | |
MA40225B1 (fr) | Composés dihydroisoquinolinone substitués | |
MX2009008338A (es) | Compuestos de piridopirimidinona de utilidad en el tratamiento de enfermedades o condiciones patologicas mediadas por los canales de sodio. | |
MA33636B1 (fr) | Dérivés aminopropioniques substitués comme inhibiteurs de néprilysine | |
MA31710B1 (fr) | (carboxylalkylenephenyl)phényloxamides, procédés pour la production de ceux-ci et utilisation de ceux-ci en tant que medicament | |
MA31170B1 (fr) | Dérivés de 2-amino-5,7-dihydro-6h-pyrrolo[3,4-d]pyrimidine servant d'inhibiteurs de la hsp-90 pour le traitement du cancer | |
MA31754B1 (fr) | Cis-imidazolines chirales | |
TNSN07275A1 (fr) | Derives de triazole substitues, servant d'antagonistes d'ocytocine | |
MA32563B1 (fr) | Dabigatran pour cathétérisme cardiaque de chirurgie percutanée | |
MA38999A1 (fr) | Nouveaux composés hétérocycliques |